TN2009000317A1 - Solid preparation comprising alogliptin and pioglitazone - Google Patents
Solid preparation comprising alogliptin and pioglitazoneInfo
- Publication number
- TN2009000317A1 TN2009000317A1 TNP2009000317A TN2009000317A TN2009000317A1 TN 2009000317 A1 TN2009000317 A1 TN 2009000317A1 TN P2009000317 A TNP2009000317 A TN P2009000317A TN 2009000317 A TN2009000317 A TN 2009000317A TN 2009000317 A1 TN2009000317 A1 TN 2009000317A1
- Authority
- TN
- Tunisia
- Prior art keywords
- pioglitazone
- solid preparation
- alogliptin
- sugar
- excipient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007023594 | 2007-02-01 | ||
PCT/JP2008/051900 WO2008093882A1 (fr) | 2007-02-01 | 2008-01-30 | Préparation solide comprenant de l'alogliptine et de la pioglitazone |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2009000317A1 true TN2009000317A1 (en) | 2010-12-31 |
Family
ID=39240362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2009000317A TN2009000317A1 (en) | 2007-02-01 | 2009-07-30 | Solid preparation comprising alogliptin and pioglitazone |
Country Status (39)
Country | Link |
---|---|
US (1) | US8637079B2 (fr) |
EP (1) | EP2107905B1 (fr) |
JP (1) | JP5284968B2 (fr) |
KR (1) | KR101486091B1 (fr) |
CN (1) | CN101646420B (fr) |
AR (1) | AR065097A1 (fr) |
AT (1) | ATE488227T1 (fr) |
AU (1) | AU2008211981B2 (fr) |
BR (1) | BRPI0807453B8 (fr) |
CA (1) | CA2677201C (fr) |
CL (1) | CL2008000279A1 (fr) |
CR (1) | CR10992A (fr) |
CY (1) | CY1111264T1 (fr) |
DE (1) | DE602008003522D1 (fr) |
DK (1) | DK2107905T3 (fr) |
DO (1) | DOP2009000195A (fr) |
EA (1) | EA015180B1 (fr) |
EC (1) | ECSP099608A (fr) |
ES (1) | ES2354397T3 (fr) |
GE (1) | GEP20125410B (fr) |
HK (1) | HK1138188A1 (fr) |
HR (1) | HRP20110094T8 (fr) |
IL (1) | IL200108A (fr) |
JO (1) | JO2650B1 (fr) |
MA (1) | MA31169B1 (fr) |
ME (1) | ME01239B (fr) |
MX (1) | MX2009008100A (fr) |
MY (1) | MY147596A (fr) |
NZ (1) | NZ579008A (fr) |
PE (1) | PE20081663A1 (fr) |
PL (1) | PL2107905T3 (fr) |
PT (1) | PT2107905E (fr) |
RS (1) | RS51592B (fr) |
SI (1) | SI2107905T1 (fr) |
TN (1) | TN2009000317A1 (fr) |
TW (2) | TWI453041B (fr) |
UA (1) | UA95828C2 (fr) |
WO (1) | WO2008093882A1 (fr) |
ZA (1) | ZA200905621B (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
CA2810522A1 (fr) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Polymorphes |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP1852108A1 (fr) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Compositions d'inhibiteurs de la DPP IV |
MY159203A (en) | 2007-07-19 | 2016-12-30 | Takeda Pharmaceuticals Co | Solid preparation comprising alogliptin and metformin hydrochloride |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
BRPI0917675A2 (pt) | 2008-08-15 | 2015-12-01 | Boehringer Ingelheim Int | compostos orgânicos para cura de ferida |
EP2344195A2 (fr) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Polythérapie pour le traitement du diabète et des états pathologiques apparentés |
UY32126A (es) | 2008-09-25 | 2010-04-30 | Takeda Pharmaceutical | Composición farmacéutica sólida |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
KR20160143897A (ko) | 2009-02-13 | 2016-12-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Dpp-4 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제 |
EA022349B1 (ru) | 2009-02-13 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Фармацевтическая композиция, включающая ингибитор sglt2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение |
BR112012012641A2 (pt) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
AU2011249771A1 (en) * | 2010-05-05 | 2012-11-01 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising pioglitazone and linagliptin |
CA2797310C (fr) | 2010-05-05 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Therapie de combinaison de l'agoniste du recepteur glp-1 et de l'inhibiteur dpp-4 |
AU2011268940B2 (en) | 2010-06-24 | 2015-05-21 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
CN101912363A (zh) * | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP2849755A1 (fr) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique |
WO2013174767A1 (fr) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires |
CN103877054B (zh) * | 2012-12-21 | 2016-05-25 | 北大方正集团有限公司 | 一种苯甲酸阿格列汀片剂及其制备方法 |
CN103156819A (zh) * | 2013-03-29 | 2013-06-19 | 山东罗欣药业股份有限公司 | 苯甲酸阿格列汀组合物片剂及其制备方法 |
WO2015128453A1 (fr) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Utilisation médicale d'un inhibiteur de dpp-4 |
WO2016104643A1 (fr) * | 2014-12-25 | 2016-06-30 | 田辺三菱製薬株式会社 | Préparation solide destinée au traitement du diabète |
WO2016202961A1 (fr) * | 2015-06-17 | 2016-12-22 | H E X A L Aktiengesellschaft | Formulation d'alogliptine |
CN108289849A (zh) * | 2015-06-26 | 2018-07-17 | 韩国联合制药株式会社 | 莫沙必利与雷贝拉唑的复合制剂 |
CN105030719B (zh) * | 2015-08-20 | 2018-07-20 | 杭州成邦医药科技有限公司 | 一种含有阿格列汀和吡格列酮的组合物 |
EP4233840A3 (fr) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinaisons de linagliptine et de metformine |
KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
CN113925838B (zh) * | 2021-11-11 | 2022-11-11 | 乐普制药科技有限公司 | 一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
EP0559702B1 (fr) | 1990-11-27 | 1994-12-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Retardateur d'urapidil |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
JP2931811B2 (ja) | 1997-06-03 | 1999-08-09 | ユニコロイド株式会社 | 徐放性カプセル |
US6030641A (en) | 1997-06-03 | 2000-02-29 | Uni Colloid Kabushiki Kaisha | Sustained release capsule and method for preparing the same |
WO1998056359A2 (fr) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Compositions retardant la liberation de principes actifs |
DE19725911A1 (de) | 1997-06-13 | 1998-12-17 | Roland Prof Dr Bodmeier | Zusammensetzungen, die die Wirkstofffreisetzung verzögern |
JP2000154137A (ja) | 1998-09-18 | 2000-06-06 | Takeda Chem Ind Ltd | 徐放性経口製剤 |
AU5652199A (en) | 1998-09-18 | 2000-04-10 | Takeda Chemical Industries Ltd. | Sustained release oral preparations |
AU5325200A (en) | 1999-06-21 | 2001-01-09 | Eli Lilly And Company | Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes |
AR030920A1 (es) | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
DK1741447T3 (da) | 2000-01-21 | 2013-12-09 | Novartis Ag | Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US7078397B2 (en) | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
AR034517A1 (es) * | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US8329217B2 (en) * | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
AU2003281181A1 (en) | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
IN192749B (fr) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
JP4567340B2 (ja) * | 2003-01-29 | 2010-10-20 | 武田薬品工業株式会社 | 被覆製剤の製造方法 |
US7976853B2 (en) * | 2003-01-29 | 2011-07-12 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
ES2556244T3 (es) | 2003-10-31 | 2016-01-14 | Takeda Pharmaceutical Company Limited | Preparación sólida que comprende pioglitazona, glimepirida y un éster de ácido graso de polioxietilensorbitán |
JP4361461B2 (ja) * | 2003-10-31 | 2009-11-11 | 武田薬品工業株式会社 | 固形製剤 |
DK3023095T3 (en) | 2004-01-20 | 2018-08-20 | Novartis Ag | Directly pressed wording and approach |
CN102140090A (zh) | 2004-03-15 | 2011-08-03 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
JP2008517921A (ja) | 2004-10-25 | 2008-05-29 | ノバルティス アクチエンゲゼルシャフト | Dpp−iv阻害剤、ppar抗糖尿病薬およびメトホルミンの組合わせ剤 |
GT200600218A (es) | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
HRP20140091T4 (hr) | 2005-09-14 | 2021-12-24 | Takeda Pharmaceutical Company Limited | Davanje inhibitora dipeptidil peptidaze |
TW200745079A (en) | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
BRPI0620020A2 (pt) | 2005-12-22 | 2011-10-25 | Takeda Pharmaceutical | preparação sólida, e, partìcula revestida |
CA2635777A1 (fr) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | Traitement combine du diabete |
-
2008
- 2008-01-30 CL CL200800279A patent/CL2008000279A1/es unknown
- 2008-01-30 BR BRPI0807453A patent/BRPI0807453B8/pt active IP Right Grant
- 2008-01-30 PL PL08704473T patent/PL2107905T3/pl unknown
- 2008-01-30 ES ES08704473T patent/ES2354397T3/es active Active
- 2008-01-30 ME MEP-2011-167A patent/ME01239B/me unknown
- 2008-01-30 JP JP2009532078A patent/JP5284968B2/ja active Active
- 2008-01-30 MX MX2009008100A patent/MX2009008100A/es active IP Right Grant
- 2008-01-30 TW TW097103417A patent/TWI453041B/zh active
- 2008-01-30 DE DE602008003522T patent/DE602008003522D1/de active Active
- 2008-01-30 AR ARP080100381A patent/AR065097A1/es not_active Application Discontinuation
- 2008-01-30 ZA ZA200905621A patent/ZA200905621B/xx unknown
- 2008-01-30 RS RS20110080A patent/RS51592B/en unknown
- 2008-01-30 EP EP08704473A patent/EP2107905B1/fr active Active
- 2008-01-30 AT AT08704473T patent/ATE488227T1/de active
- 2008-01-30 DK DK08704473.1T patent/DK2107905T3/da active
- 2008-01-30 NZ NZ579008A patent/NZ579008A/en unknown
- 2008-01-30 TW TW102128229A patent/TW201350143A/zh unknown
- 2008-01-30 MY MYPI20093188A patent/MY147596A/en unknown
- 2008-01-30 KR KR1020097017913A patent/KR101486091B1/ko active IP Right Review Request
- 2008-01-30 UA UAA200909031A patent/UA95828C2/ru unknown
- 2008-01-30 WO PCT/JP2008/051900 patent/WO2008093882A1/fr active Application Filing
- 2008-01-30 US US12/449,255 patent/US8637079B2/en active Active
- 2008-01-30 CA CA2677201A patent/CA2677201C/fr active Active
- 2008-01-30 SI SI200830149T patent/SI2107905T1/sl unknown
- 2008-01-30 PE PE2008000222A patent/PE20081663A1/es active IP Right Grant
- 2008-01-30 GE GEAP200811445A patent/GEP20125410B/en unknown
- 2008-01-30 CN CN2008800103744A patent/CN101646420B/zh active Active
- 2008-01-30 EA EA200970726A patent/EA015180B1/ru active Protection Beyond IP Right Term
- 2008-01-30 AU AU2008211981A patent/AU2008211981B2/en active Active
- 2008-01-30 PT PT08704473T patent/PT2107905E/pt unknown
- 2008-02-02 JO JO200830A patent/JO2650B1/en active
-
2009
- 2009-07-28 IL IL200108A patent/IL200108A/en active IP Right Grant
- 2009-07-30 TN TNP2009000317A patent/TN2009000317A1/fr unknown
- 2009-07-31 DO DO2009000195A patent/DOP2009000195A/es unknown
- 2009-08-06 MA MA32148A patent/MA31169B1/fr unknown
- 2009-08-24 CR CR10992A patent/CR10992A/es unknown
- 2009-08-31 EC EC2009009608A patent/ECSP099608A/es unknown
-
2010
- 2010-04-13 HK HK10103605.9A patent/HK1138188A1/xx unknown
-
2011
- 2011-02-07 HR HR20110094T patent/HRP20110094T8/xx unknown
- 2011-02-09 CY CY20111100150T patent/CY1111264T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2009000317A1 (en) | Solid preparation comprising alogliptin and pioglitazone | |
TN2010000019A1 (en) | Solid preparation comprising alogliptin and metformin hydrochloride | |
WO2008002245A3 (fr) | Nouveaux composés 385 | |
WO2007082808A3 (fr) | Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1 | |
WO2008002244A3 (fr) | Nouveaux composés 384 | |
WO2007107470A3 (fr) | Pyrazoles utiles comme inhibiteurs de 11-beta-hsd-1 | |
WO2005075425A3 (fr) | Derives de bisaryluree | |
WO2009010416A3 (fr) | Inhibiteurs de 11b-hydroxystéroïde déshydrogenase | |
EP4245299A3 (fr) | Formulations pharmaceutiques contenant un hydrate de propylèneglycol dapagliflozine | |
TW200833663A (en) | Therapeutic agents | |
BRPI0517701A (pt) | uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus | |
WO2007060140A3 (fr) | Inhibiteurs de diacylglycérol acyltransférase (dgat) | |
WO2006077025A3 (fr) | Morpholines en tant qu'agonistes de 5ht2c | |
WO2005075471A3 (fr) | Composes thiazole utilises en tant qu'inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase de type 1 | |
DE602006009095D1 (en) | Diacylglycerol-acyltransferase-hemmer | |
WO2006085113A3 (fr) | Composes chimiques | |
UA91852C2 (ru) | Фармацевтическая дозированная форма, которая содержит метформин и пиоглитазон как активные медикаменты | |
WO2008006795A3 (fr) | Composés d'indole | |
WO2007093880A3 (fr) | Nouveaux dérivés d'indolopyrone et leur procédé de préparation | |
IL188643A (en) | Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production. | |
TW200639156A (en) | New compounds | |
WO2007090661A3 (fr) | Combinaison de substances actives | |
TW200740424A (en) | Taste masking dosage form | |
WO2008074833A3 (fr) | Composés | |
WO2006133194A3 (fr) | Methodes permettant de traiter une infection virale a l'aide d'une solution medicamenteuse orale ou injectable |